Erika Hamilton: Zanidatamab Combination Shows Promising Results in HR+/HER2+ Metastatic Breast Cancer
Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute, shared a LinkedIn post about recent article she and her colleagues authored:
“Happy to share publication on zanidatamab in ER+ and HER-2 positive Breast Cancer. HER-2 antibody that binds both ECD 2 and ECD4.
This drug is also in development in other indications, including GI cancers and post T-DXd Breast Cancer with chemotherapy.”
Title: Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
Journal: The Lancet Oncology
Authors: Santiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure, Marie-France Savard, Rossanna C Pezo, Maria Gion, Manuel Ruiz-Borrego, Erika Hamilton, Timothy Pluard, Marc Webster, Muralidhar Beeram, Hannah Linden, Cristina Saura, Diana Shpektor, Bob Salim, Phoebe Harvey, Sara A Hurvitz
Erika Hamilton announced the publication of a new study evaluating zanidatamab—a bispecific HER2-targeted antibody—in combination with palbociclib and fulvestrant for patients with hormone receptor-positive, HER2-positive metastatic breast cancer.
Published in The Lancet Oncology, the phase 2a study highlights primary results from a two-part, multicenter, single-arm trial showing encouraging clinical activity in a previously treated population.
More posts featuring Erika Hamilton on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023